Gökbuget N, Stanze D, Beck J, Diedrich H, Horst H-A, Hüttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2031–41.

Article  Google Scholar 

Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oskarsson T, Söderhäll S, Arvidson J, Forestier E, Montgomery S, Bottai M, et al. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016;101:68–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park J, Rivière I, Gonen M, Wang X, Sénéchal B, Curran K, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N. Engl J Med. 2018;378:449–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rheingold S, Ji L, Xu X, Devidas M, Brown P, Gore L, et al. Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children’s Oncology Group (COG) study. J Clin Oncol. 2019;37:15_suppl:10008.

Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature. 2000;408:307–10.

Article  CAS  PubMed  Google Scholar 

Valentin R, Grabow S, Davids M. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018;132:1248–64.

Article  CAS  PubMed  Google Scholar 

Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011;2:466–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29:3185–93.

Article  PubMed  Google Scholar 

Chiaretti S, Brugnoletti F, Tavolaro S, Bonina S, Paoloni F, Marinelli M, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica. 2013;98:e59–61.

Article  PubMed  PubMed Central  Google Scholar 

Stengel, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124:251–8.

Article  CAS  PubMed  Google Scholar 

Brady S, Roberts K, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santarius T, Shipley J, Brewer D, Stratton M, Cooper C. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010;10:59–64.

Article  CAS  PubMed  Google Scholar 

Sulong S, Moorman A, Irving J, Strefford J, Konn Z, Case M, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113:100–7.

Article  CAS  PubMed  Google Scholar 

Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med. 2018;51:28–40.

Article  Google Scholar 

Zhu H, Gao H, Ji Y, Zhou Q, Du Z, Tian L, et al. Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials. J Hematol Oncol. 2022;15:91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Italiano A, Miller WH Jr, Blay J-Y, Gietema JA, Bang Y-J, Mileshkin LR, et al. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. Invest N Drugs. 2021;39:158701597.

Google Scholar 

Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124:3420–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masic D, Fee K, Bell H, Case M, Witherington G, Lansbury S, et al. Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia. Haematologica. 2023;108:981–92.

Article  CAS  PubMed  Google Scholar 

Bliss CI. The calculation of microbial assays. Bacteriol Rev. 1956;20:243–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A New Bliss Independence Model to Analyze Drug Combination Data. J Biomol Screen. 2014;19:8170821.

Article  Google Scholar 

Nemunaitis J, Young A, Ejadi S, Miller W, Chen L-C, Nichols G, et al. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharm. 2018;81:529–37.

Article  CAS  Google Scholar 

Daver N, Dail M, Garcia J, Jonas B, Yee K, Kelly K, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141:1265–76.

Article  CAS  PubMed  Google Scholar 

Lipshultz S, Adams M, Colan S, Constine L, Herman E, Hsu D, et al. Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions. Circulation. 2013;128:1927–95.

Article  PubMed  Google Scholar 

Tan T, Neilan T, Francis S, Plana J, Scherrer-Crisbie M. Anthracycline-Induced Cardiomyopathy in Adults. Compr Physiol. 2015;5:1517–40.

Article  PubMed  Google Scholar 

Roberts A, Advani R, Kahl B, Persky D, Sweetenham J, Carney D, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. BJ Haem. 2015;170:669–78.

Article  CAS  Google Scholar 

Wilson W, O’Connor O, Czuczman M, LaCasce A, Gerectiano J, Leonard J, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.

Article  CAS  PubMed  Google Scholar 

Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo P, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375–88.

Article  CAS  PubMed  Google Scholar 

Tahir S, Smith M, Hessler P, Rapp L, Idler K, Park C, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.

Article  PubMed  PubMed Central  Google Scholar 

Pan R, Ruvolo V, Mu H, Leverson J, Nichols G, Reed J, et al. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017;32:748–60.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nair A, Jacob S. A simple practice guide for dose conversion between animals and humans. J Basic Clin Pharm. 2016;7:27–31.

Article  PubMed  PubMed Central  Google Scholar 

Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, et al. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia. 2013;27:718–21.

Article  CAS  PubMed  Google Scholar 

Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A, et al. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin Cancer Res. 2015;21:1395–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaindl U, Morak M, Portsmouth C, Mecklenbräuker A, Kauer M, Zeginigg M, et al. Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia. 2014;28:600–8.

Article  CAS  PubMed  Google Scholar 

Konopleva M, Röllig C, Cavenagh J, Deeren D, Girshova L, Krauter J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6:4147–56.

CAS  PubMed  PubMed Central  Google Scholar 

Roberts A, Seymour J, Brown J, Wierda W, Kipps T, Khaw S, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–96.